Under terms of the new data license, 23andMe will provide GSK with access to de-identified, summary data from global genome- and phenome-wide analysis of the 23andMe database, for a 12-month period, and offer its research services for analyses of the data over that same period.
Wait that’s fine. That’s part of the point of 23andMe, de-identified data being used for research was always one of the selling points.
Wait that’s fine. That’s part of the point of 23andMe, de-identified data being used for research was always one of the selling points.
I mean “anonymized” data very frequently is pretty easy to de-anonymize
but yeah nobody commenting doom and gloom seems to have read the details cause its all paywalled